Undecimal Bio debuts with $18M for siRNA therapies outside the liver
Undecimal Bio has launched with $18 million in funding to develop siRNA treatments for diseases beyond the liver. The company was created as a spinout from Eleven Therapeutics after that firm separated another part of its operations earlier in the summer. It joins a field that includes RNAi-focused companies such as Arrowhead and Alnylam.
Expanded Detail
EXPANDED:
Undecimal Bio has launched with $18 million to develop siRNA-based treatments for conditions outside the liver
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Undecimal Bio launches with $18M to take siRNA beyond liver disease.” Browse more stories.